valcyte作用功效

CMV retinitis is one of the main manifestations of CMV infection and the most common ocular complication in AIDS patients, with a high incidence rate and serious consequences. The ophthalmic manifestations of CMV retinitis are different from those of retinitis caused by other causes and have more typical ophthalmic features. The successful development has saved many patients with CMV retinitis.

The U.S. Food and Drug Administration (FDA) has approved the increased use of valcyte in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease. The supplemental approval is based on data that longer-term prophylaxis with valcyte reduced the incidence of CMV disease in high-risk adult kidney transplant patients from 36.8% (for patients who received 100 days of treatment) to 16.8% (for patients who received 200 days of treatment at one year after receiving a kidney) (p < 0.0001). 1.2 The overall safety profile of valcyte did not change when prophylaxis was extended in high-risk adult kidney transplant patients.

The antiviral effect of valcyte tablets has been clinically demonstrated in the treatment of AIDS patients with newly diagnosed retinitis (clinical study WV15376). After 4 weeks of treatment with valcyte tablets, the detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55). Clinical studies of valcyte tablets in AIDS patients infected with CMV retinitis have shown that valcyte hydrochloride tablets and intravenous valcyte are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the valcyte hydrochloride group or the intravenous valcyte group for induction therapy. The proportion of patients with progression of CMV retinitis at week 4 was the same in both groups. After induction therapy, both groups of patients in the study continued to receive maintenance therapy with 900 mg of valcyte hydrochloride tablets per day. Among patients who received valcyte hydrochloride tablets or intravenous valcyte hydrochloride tablets for induction therapy followed by maintenance treatment with valcyte hydrochloride tablets, the mean (median) time from randomization to progression of CMV retinitis was: 226 (160) days and 219 (125) days. To sum up, the effect is still good.